5-溴-2-(2-甲基-1,3-二氧杂烷-2-基)吡啶 | 214701-33-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-溴-2-(2-甲基-1,3-二氧杂烷-2-基)吡啶
• 中文别名: 5-溴-2-(2-甲基-1,3-二氧戊环-2-基)吡啶
• 英文名称: 5-bromo-2-(2-methyl-1,3-dioxolan-2-yl)pyridine
• CAS: 214701-33-4
• 化学式: C₉H₁₀BrNO₂
• 分子量: 244.088
• InChiKey: WVUQSFOCAUQIMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  5-溴-2-(2-甲基-1,3-二氧杂烷-2-基)吡啶 在 乙酸铵 、 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 18.0h， 生成 2-amino-4-(3-bromophenyl)-6-[2-(4-morpholinyl)-5-pyridyl]nicotinonitrile
  参考文献：
  名称：

  5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

  摘要：

  4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.023
• 作为产物：
  描述：

  5-溴-2-[2-(三甲基硅烷基)乙炔基]吡啶 在 硫酸 、 mercury(II) diacetate 、 对甲苯磺酸 作用下， 以 水 、 丙酮 、 苯 为溶剂， 反应 4.0h， 生成 5-溴-2-(2-甲基-1,3-二氧杂烷-2-基)吡啶
  参考文献：
  名称：

  5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

  摘要：

  4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.023

文献信息

• Theramutein modulators
  申请人：Housey Gerad M.

  公开号：US20100016298A1

  公开（公告）日：2010-01-21

  This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

  这项发明涉及的是抑制或激活内源性蛋白变异形式的试剂以及识别这些变异的新方法。特别感兴趣的是那些由突变基因编码的内源性蛋白变异的抑制剂和激活剂，这些变异通常是在暴露于已知是相应未突变内源性蛋白的抑制剂或激活剂的化学试剂之后出现，或者至少是首次被识别为由此类化学试剂引起的。
• Tuning the Basicity of a Metal-Templated Brønsted Base to Facilitate the Enantioselective Sulfa-Michael Addition of Aliphatic Thiols to α,β-Unsaturated<i>N</i>-Acylpyrazoles
  作者：Xiaobing Ding、Cheng Tian、Ying Hu、Lei Gong、Eric Meggers

  DOI：10.1002/ejoc.201501494

  日期：2016.2

  The enantioselective addition of aliphatic thiols to α,β-unsaturated N-acylpyrazoles catalyzed by a bis-cyclometalated iridium(III) complex with fine-tuned Bronsted basicity was investigated. Good to excellent yields (71–99 %) and enantioselectivities (86–98 % ee) were achieved at catalyst loadings of 0.2–2.5 mol-%. In this metal-templated catalyst design, the metal serves as a structural center and

  研究了在具有微调布朗斯台德碱度的双环金属化铱 (III) 配合物催化下脂肪族硫醇与 α,β-不饱和 N-酰基吡唑的对映选择性加成。在 0.2-2.5 mol-% 的催化剂负载量下实现了良好到极好的产率 (71-99%) 和对映选择性 (86-98% ee)。在这种金属模板催化剂设计中，金属作为结构中心，催化由有机配体球通过质子转移、氢键形成和静电相互作用的组合来执行。
• Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
  申请人：HMI Medical Innovations, LLC

  公开号：US10018619B2

  公开（公告）日：2018-07-10

  This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

  本发明涉及鉴定、合成、优化和剖析作为蛋白质抑制剂或激活剂的化合物的方法，这些蛋白质既包括天然存在的内源性蛋白质，也包括内源性蛋白质的某些变体形式，以及鉴定这些变体的新方法。该方法通过改进新药鉴定、先导物优化、生物分析和快速消除有毒化合物，简化了药物发现和创造过程，从而加快了作为潜在治疗药物的化合物的鉴定和开发。该方法的实施可相应提高效率，从而降低药物发现过程的总体成本。
• Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
  申请人：HMI Medical Innovations, LLC

  公开号：US10473643B2

  公开（公告）日：2019-11-12

  This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

  本发明涉及鉴定、合成、优化和剖析作为蛋白质抑制剂或激活剂的化合物的方法，这些蛋白质既包括天然存在的内源性蛋白质，也包括内源性蛋白质的某些变体形式，以及鉴定这些变体的新方法。该方法通过改进新药鉴定、先导物优化、生物分析和快速消除有毒化合物，简化了药物发现和创造过程，从而加快了作为潜在治疗药物的化合物的鉴定和开发。该方法的实施可相应提高效率，从而降低药物发现过程的总体成本。
• [EN] HETEROARYL DERIVATIVE PARP INHIBITOR AND USE THEREOF<br/>[FR] INHIBITEUR DE PARP DÉRIVÉ D'HÉTÉROARYLE ET SON UTILISATION<br/>[ZH] 杂芳基衍生物PARP抑制剂及其用途
  申请人：[en]HAISCO PHARMACEUTICAL GROUP CO., LTD.;[zh]海思科医药集团股份有限公司

  公开号：WO2023051716A1

  公开（公告）日：2023-04-06

  提供了一种式(I)所示的化合物，其立体异构体、药学上可接受的盐、溶剂化物、共晶或氘代物，或含它们的药物组合物，及其作为PARP-1抑制剂在制备治疗相关疾病的药物中的用途。